Ligelizumab Emerging Drug Insight and Market Forecast - 2032

"Ligelizumab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ligelizumab for Chronic Spontaneous Urticaria in seven major markets. A detailed picture of the ligelizumab for Chronic Spontaneous Urticaria in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the ligelizumab for Chronic Spontaneous Urticaria. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ligelizumab market forecast analysis for Chronic Spontaneous Urticaria in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Chronic Spontaneous Urticaria.

Drug Summary:

Ligelizumab (QGE031) is a next generation monoclonal anti-immunoglobulin E (IgE) antibody being developed by Novartis Pharmaceuticals. It is thought to work by blocking the IgE/FcεRI pathway, a key driver of the inflammatory process in CSU. It has previously shown dose-dependent and time-dependent suppression of free IgE, basophil FcεRI, basophil surface IgE, and skin-prick test responses to an allergen that was superior in extent and duration to that observed with omalizumab and aims to become first-choice biologic after antihistamine therapy.

A late reaction caused by the induced synthesis and release of leukotrienes, chemokines, and cytokines by the activated mast cells allows the recruitment of other leukocytes, eosinophils, basophils, and Th2 lymphocytes to the site of inflammation. The allergic reaction includes symptoms like cough, bronchospasm, wheezing, diarrhea, and urticaria due to this process. Omalizumab binds the Cε3 domain of free IgE, preventing it from binding to FcεRI, further dampening the effector cell response to an allergen.

Compared to omalizumab, another US Food and Drug Administration (FDA)-approved mAb targeting IgE. Ligelizumab shows six-fold-nine-fold greater suppression of allergen-induced skin prick tests in vivo. The estimated plasma half-life is 20 days, with over 95% suppression of allergen-induced skin prick test responses 6 weeks post-dose by comparison with 41% for omalizumab. It also provides greater and longer suppression of free IgE and IgE on the surface of circulating basophils as compared to omalizumab. These findings suggest that ligelizumab may be more potent than omalizumab in the treatment of chronic spontaneous urticaria (CSU).

Earlier Phase IIb study results show more patients are completely symptom-free from CSU with ligelizumab than XOLAIR. Ligelizumab compared with omalizumab is currently being investigated in ongoing Phase III clinical trial programs including PEARL 1 and PEARL 2, U.S. regulatory filing in CSU is anticipated in 2022.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ligelizumab description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria.
• Elaborated details on ligelizumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ligelizumab research and development activities in Chronic Spontaneous Urticaria across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ligelizumab.
• The report contains forecasted sales of ligelizumab for Chronic Spontaneous Urticaria till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Chronic Spontaneous Urticaria.
• The report also features the SWOT analysis with analyst views for ligelizumab in Chronic Spontaneous Urticaria.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Ligelizumab Analytical Perspective by DelveInsight

• In-depth Ligelizumab Market Assessment

This report provides a detailed market assessment of ligelizumab for Chronic Spontaneous Urticaria in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• Ligelizumab Clinical Assessment

The report provides the clinical trials information of ligelizumab for Chronic Spontaneous Urticaria covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ligelizumab dominance.
• Other emerging products for Chronic Spontaneous Urticaria are expected to give tough market competition to ligelizumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ligelizumab in Chronic Spontaneous Urticaria.
• Our in-depth analysis of the forecasted sales data of ligelizumab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ligelizumab in Chronic Spontaneous Urticaria.

Key Questions

• What is the product type, route of administration and mechanism of action of ligelizumab?
• What is the clinical trial status of the study related to ligelizumab in Chronic Spontaneous Urticaria and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ligelizumab development?
• What are the key designations that have been granted to ligelizumab for Chronic Spontaneous Urticaria?
• What is the forecasted market scenario of ligelizumab for Chronic Spontaneous Urticaria?
• What are the forecasted sales of ligelizumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ligelizumab for Chronic Spontaneous Urticaria?
• Which are the late-stage emerging therapies under development for the treatment of Chronic Spontaneous Urticaria?